Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 6/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.43 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729848 | 0.92 | PRKAA2 (0.44) | FPR2PROKR1MMP2MMP13SPR | |
| SCHEMBL22729594 | 0.80 | SPR (0.38) | KCNH2FPR2PROKR1SPREPHX2 | |
| SCHEMBL22729777 | 0.79 | MMP13 (0.44) | NTRK1KCNH2NTRK2NTRK3FPR2 | |
| SCHEMBL22729674 | 0.78 | MGLL (0.37) | KCNH2MMP2SPREPHX2MGLL | |
| SCHEMBL22729461 | 0.74 | KCNH2 (0.41) | KCNH2FPR2PROKR1SPREPHX2 | |
| SCHEMBL22729427 | 0.74 | KCNH2 (0.44) | KCNH2MGLL | |
| SCHEMBL22729794 | 0.74 | MAPT (0.45) | KCNH2SPR | |
| SCHEMBL29839366 | 0.74 | CNR1 (0.41) | SPRCNR1MGLL | |
| SCHEMBL29839340 | 0.73 | CACNB4 (0.45) | SPRCNR1MGLL | |
| SCHEMBL29839304 | 0.72 | MAPT (0.39) | EPHX2CNR1HSD11B1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NTRK1 4856/4885KCNH2 2434/4885NTRK2 4122/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | NTRK1 4858/4885KCNH2 2533/4885NTRK2 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.